Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke – A Systematic Review and Meta-Analysis

Abstract

BackgroundMesenchymal stem cells (MSCs) is an attractive candidate in regenerative research and clinical trials have assessed their therapeutic potential in different neurological conditions with disparate etiologies. In this systematic review, we aimed to assess safety and clinical effect of MSC treatment in traumatic spinal cord injury (TSCI), multiple sclerosis (MS) and ischemic stroke (IS).MethodsA systematic search was performed 2021-12-10 in MEDLINE, EMBASE, Web of Science and Cochrane where clinical studies assessing MSC treatment in TSCI, MS or IS were included. Studies without control group were excluded for efficacy analysis, but included in the safety analysis. For efficacy, AIS score, EDSS score and mRS were used as clinical endpoints and assessed in a meta-analysis using the random effects model.FindingsOf 5,548 identified records, 54 studies were included. Twenty-six studies assessed MSC treatment in TSCI, 14 in MS and nine in IS, of which seven, seven and five studies were controlled, respectively. There were seven serious adverse events (SAEs), of which four were related to the surgical procedure and included one death due to complications following the implantation of MSCs. Three SAEs were considered directly related to the MSC treatment and all these had a transient course. In TSCI, a meta-analysis showed no difference in conversion from AIS A to C and a trend toward more patients treated with MSCs improving from AIS A to B as compared to controls (p = 0.05). A subgroup analysis performed per protocol, showed more MSC treated patients improving from AIS A to C in studies including patients within 8 weeks after injury (p = 0.04). In MS and IS, there were no significant differences in clinical outcomes between MSC treated patients and controls as measured by EDSS and mRS, respectively.InterpretationMSC-treatment is safe in patients with TSCI, MS and IS, although surgical implantation of MSC led to one fatal outcome in TSCI. There was no clear clinical benefit of MSC treatment, but this is not necessarily a proof of inefficacy due to the low number of controlled studies. Future studies assessing efficacy of MSC treatment should aim to do this in randomized, controlled studies.

Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis

“…In Kvistad CE. et al., review, fever and headache were the most common AEs, irrespective of administration mode [ 57 ]. Analysis of AEs in twelve studies with 502 patients receiving mesenchymal stem cell transplantation showed that the commonly reported mild AEs included fever, headache, and neuropathic pain [ 58 ].…”

Neural regeneration in the human central nervous system—from understanding the underlying mechanisms to developing treatments. Where do we stand today?

“…The administration of MSCs have also been assessed in SCI, either via intrathecal or intraoperative injections ( 145 ). Similar to the trials assessing NSCs, most of these were open-label trials designed to show feasibility and safety without a control group.…”

Introduction aux cellules souches

“…-Dans la SEP progressive, plusieurs essais cliniques suggèrent un effet potentiel de la greffe de cellules souches mésenchymateuses sur la progression du handicap que ce soit par voir IV ou par voie intra thécale 21,22 . D'autres maladies neurologiques, comme la chorée de huntington, l'AVC ischémique, la maladie d'alzeihmer font également l'objet d'essais cliniques de thérapie cellulaire.…”